Global and United States Constrained Peptide Drugs Market Report & Forecast 2022-2028

Table of Contents

1 Study Coverage

• 1.1 Constrained Peptide Drugs Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million) Introduction
• 1.2 Global Constrained Peptide Drugs Outlook 2017 VS 2022 VS 2028
  • 1.2.1 Global Constrained Peptide Drugs Market Size for the Year 2017-2028
  • 1.2.2 Global Constrained Peptide Drugs Market Size for the Year 2017-2028
• 1.3 Constrained Peptide Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
  • 1.3.1 The Market Share of United States Constrained Peptide Drugs in Global, 2017 VS 2022 VS 2028
  • 1.3.2 The Growth Rate of Constrained Peptide Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
• 1.4 Constrained Peptide Drugs Market Dynamics
  • 1.4.1 Constrained Peptide Drugs Industry Trends
  • 1.4.2 Constrained Peptide Drugs Market Drivers
  • 1.4.3 Constrained Peptide Drugs Market Challenges
  • 1.4.4 Constrained Peptide Drugs Market Restraints
• 1.5 Study Objectives
• 1.6 Years Considered

2 Constrained Peptide Drugs by Type

• 2.1 Constrained Peptide Drugs Market Segment by Type
  • 2.1.1 Cyclic Peptides
  • 2.1.2 Disulfide-Rich Peptides (DRPs)
• 2.2 Global Constrained Peptide Drugs Market Size by Type (2017, 2022 & 2028)
• 2.3 Global Constrained Peptide Drugs Market Size by Type (2017-2028)
• 2.4 United States Constrained Peptide Drugs Market Size by Type (2017, 2022 & 2028)
• 2.5 United States Constrained Peptide Drugs Market Size by Type (2017-2028)

3 Constrained Peptide Drugs by Application

• 3.1 Constrained Peptide Drugs Market Segment by Application
  • 3.1.1 Hospital
  • 3.1.2 Institute of Biology
  • 3.1.3 Others
• 3.2 Global Constrained Peptide Drugs Market Size by Application (2017, 2022 & 2028)
• 3.3 Global Constrained Peptide Drugs Market Size by Application (2017-2028)
• 3.4 United States Constrained Peptide Drugs Market Size by Application (2017, 2022 & 2028)
• 3.5 United States Constrained Peptide Drugs Market Size by Application (2017-2028)

4 Global Constrained Peptide Drugs Competitor Landscape by Company

• 4.1 Global Constrained Peptide Drugs Market Size by Company
  • 4.1.1 Top Global Constrained Peptide Drugs Companies Ranked by Revenue (2021)
  • 4.1.2 Global Constrained Peptide Drugs Revenue by Player (2017-2022)
• 4.2 Global Constrained Peptide Drugs Concentration Ratio (CR)
  • 4.2.1 Constrained Peptide Drugs Market Concentration Ratio (CR) (2017-2022)
  • 4.2.2 Global Top 5 and Top 10 Largest Companies of Constrained Peptide Drugs in 2021
  • 4.2.3 Global Constrained Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 4.3 Global Constrained Peptide Drugs Headquarters, Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million) Type
  • 4.3.1 Global Constrained Peptide Drugs Headquarters and Area Served
  • 4.3.2 Global Constrained Peptide Drugs Companies Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million) Type
  • 4.3.3 Date of International Companies Enter into Constrained Peptide Drugs Market
• 4.4 Companies Mergers & Acquisitions, Expansion Plans
• 4.5 United States Constrained Peptide Drugs Market Size by Company
  • 4.5.1 Top Constrained Peptide Drugs Players in United States, Ranked by Revenue (2021)
  • 4.5.2 United States Constrained Peptide Drugs Revenue by Players (2020, 2021 & 2022)

5 Global Constrained Peptide Drugs Market Size by Region

• 5.1 Global Constrained Peptide Drugs Market Size by Region: 2017 VS 2022 VS 2028
• 5.2 Global Constrained Peptide Drugs Market Size by Region (2017-2028)
  • 5.2.1 Global Constrained Peptide Drugs Market Size by Region: 2017-2022
  • 5.2.2 Global Constrained Peptide Drugs Market Size by Region (2023-2028)

6 Segment in Region Level & Country Level

• 6.1 North America
  • 6.1.1 North America Constrained Peptide Drugs Market Size YoY Growth 2017-2028
  • 6.1.2 North America Constrained Peptide Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.1.3 United States
  • 6.1.4 Canada
• 6.2 Asia-Pacific
  • 6.2.1 Asia-Pacific Constrained Peptide Drugs Market Size YoY Growth 2017-2028
  • 6.2.2 Asia-Pacific Constrained Peptide Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
  • 6.2.3 China
  • 6.2.4 Japan
  • 6.2.5 South Korea
  • 6.2.6 India
  • 6.2.7 Australia
  • 6.2.8 China Taiwan
  • 6.2.9 Indonesia
  • 6.2.10 Thailand
  • 6.2.11 Malaysia
• 6.3 Europe
  • 6.3.1 Europe Constrained Peptide Drugs Market Size YoY Growth 2017-2028
  • 6.3.2 Europe Constrained Peptide Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.3.3 Germany
  • 6.3.4 France
  • 6.3.5 U.K.
  • 6.3.6 Italy
  • 6.3.7 Russia
• 6.4 Latin America
  • 6.4.1 Latin America Constrained Peptide Drugs Market Size YoY Growth 2017-2028
  • 6.4.2 Latin America Constrained Peptide Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.4.3 Mexico
  • 6.4.4 Brazil
  • 6.4.5 Argentina
  • 6.4.6 Colombia
• 6.5 Middle East and Africa
  • 6.5.1 Middle East and Africa Constrained Peptide Drugs Market Size YoY Growth 2017-2028
  • 6.5.2 Middle East and Africa Constrained Peptide Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.5.3 Turkey
  • 6.5.4 Saudi Arabia
  • 6.5.5 UAE

7 Company Profiles

• 7.1 Aileron Therapeutics, Inc
  • 7.1.1 Aileron Therapeutics, Inc Company Details
  • 7.1.2 Aileron Therapeutics, Inc Business Overview
  • 7.1.3 Aileron Therapeutics, Inc Constrained Peptide Drugs Introduction
  • 7.1.4 Aileron Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.1.5 Aileron Therapeutics, Inc Recent Development
• 7.2 Bicycle Therapeutics, PLC
  • 7.2.1 Bicycle Therapeutics, PLC Company Details
  • 7.2.2 Bicycle Therapeutics, PLC Business Overview
  • 7.2.3 Bicycle Therapeutics, PLC Constrained Peptide Drugs Introduction
  • 7.2.4 Bicycle Therapeutics, PLC Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.2.5 Bicycle Therapeutics, PLC Recent Development
• 7.3 Polyphor Limited
  • 7.3.1 Polyphor Limited Company Details
  • 7.3.2 Polyphor Limited Business Overview
  • 7.3.3 Polyphor Limited Constrained Peptide Drugs Introduction
  • 7.3.4 Polyphor Limited Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.3.5 Polyphor Limited Recent Development
• 7.4 Protagonist Therapeutics, Inc
  • 7.4.1 Protagonist Therapeutics, Inc Company Details
  • 7.4.2 Protagonist Therapeutics, Inc Business Overview
  • 7.4.3 Protagonist Therapeutics, Inc Constrained Peptide Drugs Introduction
  • 7.4.4 Protagonist Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.4.5 Protagonist Therapeutics, Inc Recent Development
• 7.5 Santhera Pharmaceuticals Holding
  • 7.5.1 Santhera Pharmaceuticals Holding Company Details
  • 7.5.2 Santhera Pharmaceuticals Holding Business Overview
  • 7.5.3 Santhera Pharmaceuticals Holding Constrained Peptide Drugs Introduction
  • 7.5.4 Santhera Pharmaceuticals Holding Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.5.5 Santhera Pharmaceuticals Holding Recent Development
• 7.6 Union Chimique Belge S.A. (UCB)
  • 7.6.1 Union Chimique Belge S.A. (UCB) Company Details
  • 7.6.2 Union Chimique Belge S.A. (UCB) Business Overview
  • 7.6.3 Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Introduction
  • 7.6.4 Union Chimique Belge S.A. (UCB) Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.6.5 Union Chimique Belge S.A. (UCB) Recent Development
• 7.7 Pepscan Therapeutics B.V.
  • 7.7.1 Pepscan Therapeutics B.V. Company Details
  • 7.7.2 Pepscan Therapeutics B.V. Business Overview
  • 7.7.3 Pepscan Therapeutics B.V. Constrained Peptide Drugs Introduction
  • 7.7.4 Pepscan Therapeutics B.V. Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.7.5 Pepscan Therapeutics B.V. Recent Development
• 7.8 Pepticom Ltd.
  • 7.8.1 Pepticom Ltd. Company Details
  • 7.8.2 Pepticom Ltd. Business Overview
  • 7.8.3 Pepticom Ltd. Constrained Peptide Drugs Introduction
  • 7.8.4 Pepticom Ltd. Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.8.5 Pepticom Ltd. Recent Development
• 7.9 PeptiDream, Inc.
  • 7.9.1 PeptiDream, Inc. Company Details
  • 7.9.2 PeptiDream, Inc. Business Overview
  • 7.9.3 PeptiDream, Inc. Constrained Peptide Drugs Introduction
  • 7.9.4 PeptiDream, Inc. Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.9.5 PeptiDream, Inc. Recent Development
• 7.10 CPC Scientific Inc.
  • 7.10.1 CPC Scientific Inc. Company Details
  • 7.10.2 CPC Scientific Inc. Business Overview
  • 7.10.3 CPC Scientific Inc. Constrained Peptide Drugs Introduction
  • 7.10.4 CPC Scientific Inc. Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.10.5 CPC Scientific Inc. Recent Development
• 7.11 Creative Peptides
  • 7.11.1 Creative Peptides Company Details
  • 7.11.2 Creative Peptides Business Overview
  • 7.11.3 Creative Peptides Constrained Peptide Drugs Introduction
  • 7.11.4 Creative Peptides Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.11.5 Creative Peptides Recent Development
• 7.12 Bio-Synthesis Inc
  • 7.12.1 Bio-Synthesis Inc Company Details
  • 7.12.2 Bio-Synthesis Inc Business Overview
  • 7.12.3 Bio-Synthesis Inc Constrained Peptide Drugs Introduction
  • 7.12.4 Bio-Synthesis Inc Revenue in Constrained Peptide Drugs Business (2017-2022)
  • 7.12.5 Bio-Synthesis Inc Recent Development

8 Research Findings and Conclusion

9 Appendix

• 9.1 Research Methodology
  • 9.1.1 Methodology/Research Approach
  • 9.1.2 Data Source
• 9.2 Author Details